Literature DB >> 23307753

The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.

D Jantas1, A Roman, J Kuśmierczyk, E Lorenc-Koci, J Konieczny, T Lenda, W Lasoń.   

Abstract

The proteasome inhibition and mitochondrial dysfunction are involved in pathomechanism of Parkinson's disease. The main aim of this study was to assess how particular culture conditions of human dopaminergic neuroblastoma SH-SY5Y cells could affect the extent of neurodegeneration induced by proteasome inhibitor-lactacystin (LC) and mitochondrial toxin-rotenone (Rot). This study revealed that induction of neuronal differentiation of SH-SY5Y cells with retinoic acid (RA-SH-SY5Y) caused a higher resistance of these cells to LC-evoked cell death when compared to undifferentiated cells (UN-SH-SY5Y). In contrast, RA-SH-SY5Y cells were more vulnerable than the UN-SH-SY5Y to Rot-induced cell damage. Furthermore, we found that a prolonged incubation of the cells under low serum condition (PLSC) significantly increased the LC toxicity in both differentiated and undifferentiated cells. Next, the effects of combined treatment with LC and Rot on cell viability were studied in RA-SH-SY5Y cells under PLSC and normal low serum condition (NLSC). At a low concentration, Rot (0.001-1 μM) attenuated the LC-evoked cell death in RA-SH-SY5Y cells exposed to NLSC. In contrast, under PLSC low concentrations of Rot lacked neuroprotective action while its higher levels (10 μM) enhanced the LC toxicity. Further, we showed that low concentrations of celastrol (Cel; 0.001 μM), a putative neuroprotective agent with antioxidant and anti-inflammatory properties, were able to partially attenuate the Rot-evoked toxicity under both PLSC and NLSC. On the other hand, Cel (0.001 and 0.01 μM) attenuated the LC-induced cell damage only under PLSC. Interestingly, higher concentrations of Cel (>1 μM) reduced cell viability in both UN- and RA-SH-SY5Y but only in UN-SH-SY5Y cells the effect was enhanced under PLSC. The obtained data indicate that toxicity of LC and Rot in SH-SY5Y cell line depends on the stage of cell differentiation and is enhanced in cells cultured for a longer time in low serum medium. Moreover, the neuroprotective properties of Rot and Cel against the LC-induced cell damage can be observed only under particular low serum conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307753     DOI: 10.1007/s12640-012-9374-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  92 in total

1.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.

Authors:  Sheila M Fleming; Chunni Zhu; Pierre-Olivier Fernagut; Arpesh Mehta; Cheryl D DiCarlo; Ronald L Seaman; Marie-Françoise Chesselet
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

2.  Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.

Authors:  Hardy J Rideout; Isabelle C J Lang-Rollin; Magali Savalle; Leonidas Stefanis
Journal:  J Neurochem       Date:  2005-06       Impact factor: 5.372

Review 3.  Parkinson's disease: the genetics of a heterogeneous disorder.

Authors:  D Gosal; O A Ross; M Toft
Journal:  Eur J Neurol       Date:  2006-06       Impact factor: 6.089

4.  Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures.

Authors:  Jaehong Suh; Young Ae Lee; Byoung Joo Gwag
Journal:  J Neurochem       Date:  2005-09-02       Impact factor: 5.372

5.  Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents.

Authors:  D S Middlemas; B K Kihl; N M Moody
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.

Authors:  Günter U Höglinger; Géraldine Carrard; Patrick P Michel; Fadia Medja; Anne Lombès; Merle Ruberg; Bertrand Friguet; Etienne C Hirsch
Journal:  J Neurochem       Date:  2003-09       Impact factor: 5.372

7.  Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo.

Authors:  Tianhong Pan; Wen Zhu; Hongru Zhao; Hao Deng; Wenjie Xie; Joseph Jankovic; Weidong Le
Journal:  Brain Res       Date:  2008-05-20       Impact factor: 3.252

8.  Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.

Authors:  Keiko Imamura; Takao Takeshima; Kazuhiro Nakaso; Satoru Ito; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2008-05-23       Impact factor: 3.046

Review 9.  Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Ramaswamy Kannappan; Bharat B Aggarwal
Journal:  Toxins (Basel)       Date:  2010-10-22       Impact factor: 4.546

10.  Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent.

Authors:  Mariarosaria Miloso; Daniela Villa; Marco Crimi; Stefania Galbiati; Elisabetta Donzelli; Gabriella Nicolini; Giovanni Tredici
Journal:  J Neurosci Res       Date:  2004-01-15       Impact factor: 4.164

View more
  9 in total

1.  Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.

Authors:  Jaewang Lee; Min Park; Min Ho Lee; Hyun Jun Woo; Hyun-Woo Kim; Ji Yeong Yang; Yong-Bin Eom; Sa-Hyun Kim; Changyoung Yoo; Jong-Bae Kim
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

3.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

4.  PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglodi; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-04-17       Impact factor: 3.911

5.  Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.

Authors:  Jolanta Konieczny; Danuta Jantas; Tomasz Lenda; Helena Domin; Anna Czarnecka; Katarzyna Kuter; Maria Śmiałowska; Władysław Lasoń; Elżbieta Lorenc-Koci
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

Review 6.  Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases.

Authors:  Rita Cascão; João E Fonseca; Luis F Moita
Journal:  Front Med (Lausanne)       Date:  2017-06-15

7.  Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells.

Authors:  Bin Peng; Xue Zhang; Fanfan Cao; Ying Wang; Limin Xu; Lu Cao; Chunxin Yang; Maoquan Li; Georges Uzan; Denghai Zhang
Journal:  BMC Cancer       Date:  2014-03-04       Impact factor: 4.430

8.  Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity.

Authors:  Shulei Lei; Laura Zavala-Flores; Aracely Garcia-Garcia; Renu Nandakumar; Yuting Huang; Nandakumar Madayiputhiya; Robert C Stanton; Eric D Dodds; Robert Powers; Rodrigo Franco
Journal:  ACS Chem Biol       Date:  2014-07-07       Impact factor: 5.100

9.  Comment on: "Cytotoxicity of Oxycodone and Morphine in Human Neuroblastoma and Mouse Motoneuronal Cells: A Comparative Approach".

Authors:  Richard B Parsons
Journal:  Drugs R D       Date:  2016-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.